Zum Inhalt springen

Ultra-processed food:  higher risk of early death

Higher consumption of most ultra-processed foods is linked to a slightly higher risk of death, with ready-to-eat meat, poultry, and seafood based products, sugary drinks, dairy based desserts, and highly processed breakfast foods showing the strongest associations, finds a 30-year US study in The BMJ today. The researchers say not all ultra-processed food products should be universally restricted, but that their findings “provide support for limiting consumption of certain types of ultra-processed food for long term health.” Ultra-processed foods include packaged baked goods and snacks, fizzy drinks, sugary cereals, and ready-to-eat or heat products. They often contain colours, emulsifiers, flavours, and other additives and are typically high in energy, added sugar, saturated fat, and salt, but lack vitamins and fibre. Mounting evidence links ultra-processed foods to higher risks of obesity, heart disease, diabetes and bowel cancer, but few long term… 

Telomere findings offer new insights for cancer treatments

A new study led by University of Pittsburgh and UPMC Hillman Cancer Center researchers shows that an enzyme called PARP1 is involved in repair of telomeres, the lengths of DNA that protect the tips of chromosomes, and that impairing this process can lead to telomere shortening and genomic instability that can cause cancer. PARP1’s job is genome surveillance: When it senses breaks or lesions in DNA, it adds a molecule called ADP-ribose to specific proteins, which act as a beacon to recruit other proteins that repair the break. The new findings, published today in Nature Structural & Molecular Biology, are the first evidence that PARP1 also acts on telomeric DNA, opening up new avenues for understanding and improving PARP1-inhibiting cancer therapies. O’Sullivan hypothesizes that ADP-ribose affects telomere integrity by disrupting a protective structure called shelterin that safeguards telomeres, but more… 

Neue Funktion von Onkoproteinen entdeckt

Forscher der Universität Würzburg haben eine neue Funktion des Onkoproteins MYCN entdeckt: Es trägt nicht nur dazu bei, dass Krebszellen stärker werden, sondern macht sie auch resistenter gegen Medikamente. Onkoproteine sind tatsächlich überlebenswichtig für den Menschen: Tausende von ihnen sorgen in unserem Körper dafür, dass Zellen wachsen und sich teilen. Sie helfen, Wunden zu heilen, genetische Schäden zu reparieren und unser Immunsystem zu stärken. Doch wenn Onkoproteine nicht mehr richtig funktionieren, kann es gefährlich werden – sie verursachen unkontrolliertes Zellwachstum und Tumore. Das Onkoprotein MYCN beispielsweise ist die Ursache vieler aggressiver Krebsarten und Tumoren, von denen insbesondere Kinder betroffen sind. „MYCN-Proteine regulieren die Produktion von Boten-RNA (mRNA) im Zellkern und damit die Produktion von Proteinen, die das Zellwachstum fördern“, erklärt Martin Eilers, Leiter des Fachbereichs Biochemie und Molekularbiologie an der Universität Würzburg (JMU). Deuschland. „Wenn dieser Prozess außer Kontrolle gerät,… 

Telemedizin und Digital-Health in Frankreich

Vor dem Hintergrund eines dramatischen Hausärztemangels hat sich die Telemedizin in Frankreich in den letzten Jahren stark entwickelt. Hier sind ausgewählte Telemedizin – und Digital-Health-Lösungen aus Frankreich. Telemedizin und Digital-Health in Frankreich

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day. Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

CRISPR Therapeutics Highlights ASGCT Oral Presentation

– ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma – CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer

LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) — Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting. Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting

Recce Pharmaceuticals Granted New Patent in China

SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives

Novant Health und Michael Jordan arbeiten zusammen

Novant Health mit Sitz in Winston-Salem, North Carolina, hat sich mit dem ehemaligen Profi-Basketballspieler Michael Jordan zusammengetan, um eine neue medizinische Klinik zu eröffnen. Laut einer Pressemitteilung von Novant vom 7. Mai wurde die neue 7.800 Quadratmeter große Klinik mit dem Namen Novant Health Michael Jordan Family Medical Clinic in Wilmington, North Carolina, der Heimatstadt… Novant Health und Michael Jordan arbeiten zusammen, um den Zugang zur Gesundheitsversorgung zu erweitern

Filigree mesh: the new absorbable stent. Copyright: Karin Kaiser / MHH

MHH Cardiology implants self-dissolving stents

High-Tech Cardiology Made in Lower Saxony. Constricted coronary arteries harbor dangers: Because the heart is not supplied with blood properly, this can lead to pain, cardiac arrhythmia, cardiac insufficiency and sudden cardiac death. One way of eliminating a constriction in a vessel is to implant a stent. This involves the minimally invasive insertion of a small mesh tube into the vessel. Until now, all stents were made of metal and remained in the body, sometimes for decades, depending on the age of the patient. This has various disadvantages, but until now seemed unavoidable. Self-dissolving stents are therefore a groundbreaking innovation. The Department of Cardiology and Angiology at Hannover Medical School (MHH) is at the forefront of this field. A new type of absorbable stent from Biotronik has now been implanted in a patient there. It was the second implantation of…